Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.30 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.30 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7247702 | 1.00 | GRIN2D (0.30) | GRIN2DGRIN3BADRA1DADRA1AADRA1B | |
| SCHEMBL16620434 | 0.88 | — | — | |
| SCHEMBL16620265 | 0.88 | — | — | |
| Iodide SCHEMBL7254660 | 0.88 | — | — | |
| Iodide SCHEMBL7250541 | 0.88 | — | — | |
| SCHEMBL1032869 | 0.86 | GRIN2D (0.31) | GRIN2DGRIN3BADRA1DADRA1AADRA1B | |
| SCHEMBL6692702 | 0.85 | NPSR1 (0.30) | GRIN2DGRIN3BADRA1DADRA1AADRA1B | |
| SCHEMBL16620322 | 0.85 | NPSR1 (0.30) | GRIN2DGRIN3BADRA1DADRA1AADRA1B | |
| SCHEMBL16620763 | 0.85 | NPSR1 (0.30) | GRIN2DGRIN3BADRA1DADRA1AADRA1B | |
| SCHEMBL16620750 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6635622-B2 | Having anti-tumor activity and immunostimulating activity | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2003-10-21 | — | — | US | disclosed |
| US-20020032158-A1 | Novel glycolipid derivatives | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2002-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032158-A1 | Novel glycolipid derivatives | SGMS2, SGMS1, HACD3 | GRIN2D 2958/4885GRIN3B 3120/4885ADRA1D 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.